» Subscribe Today!
More of what you want to know.
The Daily News
X

Forgot your password?
Skip Navigation LinksHome >
VOL. 124 | NO. 122 | Wednesday, June 24, 2009

GlaxoSmithKline Gets Inflammatory Disease Partner

AP

Print | Front Page | Email this story | Comments ()

NEW YORK (AP) - British drug developer GlaxoSmithKline PLC said Tuesday it is collaborating with Chroma Therapeutics Ltd. to develop treatments for inflammatory disorders.

Chroma has the potential to receive $1 billion in milestone and option payments if all four programs under the deal are successful. The partnership will focus on using Chroma's technology to target specific cells at the root of inflammatory diseases such as rheumatoid arthritis.

During each program, Chroma is responsible for research and development activities through completion of clinical proof of concept studies. GlaxoSmithKline has the option to take the compounds to clinical trials.

Shares of GlaxoSmithKline rose 54 cents to $36.23 in Tuesday morning trading.

Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Sign-Up For Our Free Email Edition
Get the news first with our daily email


 
Blog Get more from The Daily News
Blog News, Training & Events
RECORD TOTALS DAY WEEK YEAR
PROPERTY SALES 81 217 5,290
MORTGAGES 94 276 6,985
FORECLOSURE NOTICES 22 72 1,628
BUILDING PERMITS 384 712 12,691
BANKRUPTCIES 66 241 5,541
BUSINESS LICENSES 27 85 2,146
UTILITY CONNECTIONS 52 234 7,292
MARRIAGE LICENSES 10 53 1,511

Weekly Edition

Issues | About

The Memphis News: Business, politics, and the public interest.